{"name":"Denali Therapeutics Inc.","slug":"denali-therapeutics-inc","ticker":"","exchange":"","domain":"denalitherapeutics.com","description":"","hq":"South San Francisco","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":418778000,"netIncome":-512540000,"cash":1144854000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"AVLAYAH","genericName":"TIVIDENOFUSP ALFA-EKNM","slug":"tividenofusp-alfa-eknm","indication":"Other","status":"marketed"},{"name":"DNL593","genericName":"DNL593","slug":"dnl593","indication":"Other","status":"phase_1"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"DNL343","genericName":"DNL343","slug":"dnl343","indication":"Parkinson's disease (LRRK2-associated and idiopathic)","status":"phase_2"}]}],"pipeline":[{"name":"AVLAYAH","genericName":"TIVIDENOFUSP ALFA-EKNM","slug":"tividenofusp-alfa-eknm","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"DNL343","genericName":"DNL343","slug":"dnl343","phase":"phase_2","mechanism":"DNL343 is a small-molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2) that reduces pathological protein aggregation in neurodegeneration.","indications":["Parkinson's disease (LRRK2-associated and idiopathic)"],"catalyst":""},{"name":"DNL593","genericName":"DNL593","slug":"dnl593","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwJBVV95cUxPUElSQmJxZDYzVFlJalNkVlBQSVA4NVVQOHI1N1duWFpSSnR5S0JibGlPUjF5XzJBMEdSX3Yzb3FnaElBN09oN2xDS0N1ZXZWcmJ2OUJDVlM0ZEZMMFRSQzRiM3pTWUIwU2tFOHd5emYzbVNXTnNfSUN5R09hN1FIckotbUJOMlNQTnZ4U1k1Q0FoS1ZsbzRvTzdWWUVYUkhHTlZsY1lLRGVOUmxXTVVJUXpsRTQ2cGp3a3JVOWhXM0l2am55QXhhYTdoMjQ5SjZ4M3RsQjV1cVpYbFVhQVY3ZXE0TnFodVIzeEdFUDJuaFJCRXU0ZlYyd282dTl0aUZ0NlV2d2NCVHVjOXJBUUdWMUZfZGFSaHBfOGE0?oc=5","date":"2026-04-08","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI) and Fennec Pharmaceuticals (FENC) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI) and Fennec Pharmaceuticals (FENC)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxOdFFrVjVOZm4tOFktaWlnYm5aOFBFNWFwbUQ4LVZseS1HbDNMN1NpMlpNcGVSdUpfQlVMT3hvazZ2ZVFJNDJzb0pGOGg4UzZhT3hWR2VJcUpYRlVlQ0VtdWRMSEdSSkNfZFpEQVBmWmhMREpabUdBajF5MjMwYnhXaWlMWHR3UQ?oc=5","date":"2026-04-06","type":"pipeline","source":"BioSpace","summary":"Takeda Breaks Up With Denali, Dumps Dementia Drug - BioSpace","headline":"Takeda Breaks Up With Denali, Dumps Dementia Drug","sentiment":"neutral"},{"date":"2026-04-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNbjJTT0t2Sld6SVNCVFZJeFBWa1RzUkFjZTJLZ1FqRDJCWEkwRkEyWnd2QVFwajhuR2VheVY3VDVETlhDdGZHMlJxeTM0MUs1WUY0R1N0QVpZNENGZWt4NC1SbFpxcUExaDRYR0VTdHFmazMyOHZWRllsbnFsVnF5N255R1lTcm42Y0lTUmJHTFJldVdaVFlhcERseE1jYklMUHNtMGJBMDBkUFNqYnVWc0dB?oc=5","date":"2026-03-31","type":"regulatory","source":"The Business Journals","summary":"Denali Therapeutics scores $200 million shortly after first drug approval - The Business Journals","headline":"Denali Therapeutics scores $200 million shortly after first drug approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQQU1hTGRMemY3UGk3X1UwVlFoVUJLRU9rcmNzYWk0d1o1VGROMVdLUk9nY3Y2UGhvY0lhZkFlUEljWEd2RXBPOFZOaFZPcFlxeEM3VklqLVJQUy1DMjRORmRwVmpLV2xhRUVmZHZ0WHd3UkJZRk55ZXhEMDNJTENHcXdRakpMc3BTRmJVc1NMMDJmT2J6R1I5dXJGT1pxdTdkTlk0MEZxalVQemwzQjJLeVNR?oc=5","date":"2026-03-31","type":"regulatory","source":"Stock Titan","summary":"Denali Therapeutics (NASDAQ: DNLI) closes $200M royalty deal after FDA OK - Stock Titan","headline":"Denali Therapeutics (NASDAQ: DNLI) closes $200M royalty deal after FDA OK","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxNWHJXb3VmWlctTnd6TTV0Y0o1OVVaVFYyRkczSlB1dkdHN1pXV2tjaE12MEdEb1JZM19haFdraXVyRHJIQWNWZVpHR3Y2bW1TdXhOQXFpWWNJS3k4ZlVKTE05QTdTSG9fZzVRSzctdF80M2hLcTI2WXU3RlR6R2YzcWJUQ1ZaOGMzWURUOVJFT1BpNURpQlhBMFNXaGpDMnlRNGJNLTFNQkJlaUNjR3ByeEhzcFljZkdsSkJIbl8tbmtoNU5tSFl1WUotTi1JM0ZsY3RFZlRxdXRxRUVJOGhBOWRUNzNBQ2Rucm5lZFZPSl84SWUwUHNWc3lXcw?oc=5","date":"2026-03-31","type":"regulatory","source":"Minichart","summary":"Denali Therapeutics Receives $200 Million Following FDA Accelerated Approval of Tividenofusp Alfa and Royalty Agreement Closing - Minichart","headline":"Denali Therapeutics Receives $200 Million Following FDA Accelerated Approval of Tividenofusp Alfa and Royalty Agreement ","sentiment":"positive"},{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNYmd1OXJqa1pUMnlrdFlVcDdXeVg1eXZfUUkxSno0MGQxbHZaVU1pR0xkbGZEOU00V1NUQ2x1eHlvX1hYdnN3Qlk5dzAxdVRPd0MwYVViOTNRVGxtaWJNNTJHM283WWtBZWgxUGQwcDVsR3BITW1YSmstbFd2NVJvZDNsbTQ1SWdSSDkzZ0tFbW1oRUNOSkpVbk9heGtKc1JaX1FLc1RBczFlLWhIbktZMW1iOXJkb3pGdDZBOA?oc=5","date":"2026-03-25","type":"regulatory","source":"Reuters","summary":"US FDA approves Denali's genetic disorder therapy for children - Reuters","headline":"US FDA approves Denali's genetic disorder therapy for children","sentiment":"positive"},{"date":"2026-03-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxOWHctV0c3TVE2b3Z0LU1IZHo5MHd6REdlQ2JGVy16R0c1WTBqV2FiOS1ISG9ERmdKbndSODZIaEVmcHZ5WDRrWUcwN1h6ck5mWWQ2R3lMTVMzNW9JcEdMbmpfcFIyTXZ4X01YQTdRVDBVRkVGZVA2SXppV0F0emRWT2gxUWRiVXR3eTB5NlZnRlFrT3ZtNmZTa29WS2dFbEIxRWZxSlRlSFlOc1hRcXhVS2pDSkNTdlh3aDdqaUVCMXFHTTZoTTg1VV9YNjY5NVVOS091ZTVxbGFrOXZxSlBpbk9FSUZ4ZzU4Snc?oc=5","date":"2026-03-09","type":"pipeline","source":"Benzinga","summary":"Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On - Benzinga","headline":"Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQaGZaendLNlBmQmtqTm1ELTdrVktjTFJLdEE2NXFFZEJWR3h2QV9sZmRNbER2MVVJeDQ0X2lCSXVIcm0tejBxeTNvMkpWanJnaXNmVmRLeEdOUmJiR1p3c21UUDlZTHdHRjE2cVg4OElQNTB2WC1KX25fTFdjZ3U3anliV0tRZ0RfTUhnaV96ai00NlQ3OXBVRjlzWXVmWVY1MTg0eQ?oc=5","date":"2025-12-29","type":"pipeline","source":"NAI500","summary":"Towards 2026, Focusing on Three High-Potential Biotechnology Companies - NAI500","headline":"Towards 2026, Focusing on Three High-Potential Biotechnology Companies - NAI500","sentiment":"neutral"},{"date":"2025-12-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":1,"phase_2":1,"phase_1":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":0,"period":"2025-12-31"},{"value":0,"period":"2024-12-31"},{"value":0,"period":"2024-12-31"},{"value":330531000,"period":"2023-12-31"},{"value":330531000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":418778000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-512540000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":1144854000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}